Masaaki Sawa

12PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyAllergyMolecular targetsCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 07, 2026
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.

|Mar 20, 2025
Discovery of HM-279, a Potent Inhibitor of ALK5 for Improving Therapeutic Efficacy of Cancer Immunotherapy.

Mai Arai, Mitsuharu Hanada, Haruka Taniguchi

|Nov 11, 2024
Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study.

Kyoko Miyamoto, Robert M Miller, Christine Voors-Pette

|Sep 22, 2023
CDC7 kinase inhibitors: a survey of recent patent literature (2017-2022).

Takayuki Irie, Masaaki Sawa

|Apr 20, 2023
BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing.

Miruto Tanaka, Shinsuke Nakamura, Tomohisa Sakaue

|Oct 05, 2021
Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers.

Takayuki Irie, Tokiko Asami, Ayako Sawa

Pageof 2

Frequent Collaborators

2 joint publications

Wataru Kawahata

2 joint publications

Takayuki Irie

2 joint publications

Kyoko Miyamoto

1 joint publications

Hisao Masai